✦
Neuralink has announced Blindsight, a new device designed to restore sight to people who are completely blind. The announcement was made on 30 October, when Elon Musk wrote on X that the product was technically ready and that regulatory approval was now the remaining step.
Blindsight is Neuralink's second product, following Telepathy, the brain implant introduced in 2024. While Telepathy is designed to let people control a computer with their thoughts, Blindsight aims to give vision to people who have never seen, including those who were born blind. Musk said the device would allow even people who are completely blind or have never seen to see, a claim that will need to be tested in clinical trials before it can be judged. For people who have lost their sight entirely, existing treatments offer little, and a working implant would be a major step, although the path from announcement to approved treatment usually takes years of trials.
Neuralink has not published detailed results for Blindsight, and the device has not yet been approved for use in people. Brain implants face some of the strictest safety checks in medicine, because they involve surgery and a device that stays in the body. Regulators will want evidence that the implant is safe, that it works as claimed, and that any vision it provides is genuinely useful to the person receiving it.
The announcement is the latest in a series of bold claims from Musk about Neuralink's work. The company has moved quickly from its first human implants to new products, and it has a history of announcing ambitious goals before the evidence is public. That has drawn both excitement and caution from scientists, who note that restoring sight is one of the hardest problems in neuroscience.
For people living with blindness, the news will be welcome but should be read carefully. A device that is technically ready in the lab is still a long way from a treatment that doctors can offer, and the timeline will depend on trials and approvals rather than announcements.
Source: Izvestia
